ライフサイエンスコーパス: PCO

1 PCO analysis revealed clear genetic differentiation of t

2 PCO characteristics are extensive extracellular matrix (

3 PCO development and the influence of the anterior capsul

4 PCO incidence was higher in: (1) eyes operated on by jun

5 PCO is caused by residual lens cells undergoing one of t

6 PCO measurement compared well with the lithium dilution

7 PCO pretreatment improved LV myocyte contractile functio

8 PCO was evaluated clinically and histopathologically.

9 PCO(2) was determined by measuring the rate of intracell

10 PCOs address only the topics specifically identified in

11 PCOs are not continually updated and may not reflect the

12 PCOs cannot account for individual variation among patie

13 PCOs cannot account for individual variation among patie

14 y reperfusion and rewarming (n = 8); and (2) PCO/cardioplegia: institution of CPB, antegrade myocardi

15 espiratory stimuli include changes in PO(2), PCO(2), central respiratory drive, or respiratory mechan

16 ive secondary analyses from RCTs in the 2012 PCO on providing palliative care services to patients wi

17 The 2012 PCO was based on a review of a randomized controlled tri

18 ll as secondary analyses of RCTs in the 2012 PCO, published from March 2010 to January 2016.

19 lkalosis (pH, 7.43; normal range, 7.35-7.42; PCO(2), 26 mmHg; normal range, 38-42 mmHg; PO(2), 89 mmH

20 w evidence may have emerged since the time a PCO was submitted for publication.

21 w evidence may have emerged since the time a PCO was submitted for publication.

22 e 59.1% of non-genitoplasty papers addressed PCOs in some form, only 4.3% used instruments partially-

23 blots assessed AKT/ERK involvement 2 h after PCO.

24 known about its effects on infarction after PCO.

25 unction were measured 48 h and 3 weeks after PCO.

26 matory reaction, capsular fibrosis, ACO, and PCO.

27 ore steeply when ventilation was altered and PCO(2) was constant.

28 that the proteasome can mediate cataract and PCO-associated changes and therefore is a novel target o

29 cated PEX, the risks of IOL decentration and PCO were low and comparable to that in control subjects.

30 tcome measures included IOL decentration and PCO.

31 Arterial pH decreased and PCO(2) increased with increasing eosinophil count.

32 ous NaHCO(3) concentration (10(-5)-1 M), and PCO(2) (0-1 atm).

33 The relation between PCO morphology and PCO severity and the precapsulotomy and postcapsulotomy

34 reactivity of the 2-phosphaethynolate anion (PCO(-)) towards a cyclic trisilene (cSi3(Tip)4) is repor

35 Reactions of the 2-phosphaethynolate anion (PCO(-), 1) with ammonium salts quantitatively yielded ph

36 Accordingly, adherence to any PCO is voluntary, with the ultimate determination regard

37 Apparent PCO(2) of BCEC (0.0036 +/- 0.00023 cm/sec) was not diffe

38 atients were stratified into 5 mm Hg arrival PCO(2) increments.

39 The proportion of arrival PCO(2) values within the optimal range was lower for int

40 proved survival was observed for the arrival PCO(2) range 30-49 mm Hg.

41 Outcomes for patients with arrival PCO(2) values inside and outside this optimal range were

42 Patients with arrival PCO(2) values inside this optimal range had improved sur

43 Arterial PCO(2) is tightly regulated via changes in breathing.

44 te breathing to maintain a constant arterial PCO(2) (PaCO(2))].

45 ASCO PCOs describe the use of procedures and therapies in cli

46 ASCO PCOs describe the use of procedures and therapies in cli

47 +)(221-Kryptofix)] salts containing AsCO(-), PCO(-), and PCS(-) anions were successfully electrospray

48 ntifies PCO, but also qualitatively assesses PCO in an automated manner with texture classification.

49 gavage to 250 g male rats for 10 days before PCO and was continued afterward.

50 ether these influenced the agreement between PCO and LiCO methods.

51 The relation between PCO morphology and PCO severity and the precapsulotomy a

52 ty, whereas the curvilinear relation between PCO severity and logMAR indicates that logMAR is unaffec

53 er capsulotomy differs significantly between PCO types (p = 0.005, Kruskal-Wallis test).

54 Suppression of SFK activation blocked PCO, suggesting SFKs as a therapeutic target for the pre

55 cells that are sensitive to changes in brain PCO(2) or pH and contribute to the stimulation of breath

56 contour CO (PCO) method, CO was measured by PCO and by LiCO methods at 4, 8, 16, and 24 hrs.

57 We find pre-CAMP PCO(2) values of ~2000 parts per million (ppm), increasi

58 In human cells, PCO-C (250 mug/mL) inhibited the production of intracell

59 enchymal transition (EMT) that characterizes PCO were observed in the presence and absence of the mat

60 initial calibration of the pulse contour CO (PCO) method, CO was measured by PCO and by LiCO methods

61 rr, PO2 approximately 120 Torr) and high CO (PCO approximately 550 Torr, PO2 approximately 120 Torr)

62 investigated the use of principle component (PCO) analysis as one approach to elucidate population st

63 curves demonstrated a right shift in control PCO animals, whereas the (-)-epicatechin curves were com

64 ased on the model material PrxCe1-xO2-delta (PCO).

65 p-Methoxycinnamic diester (PCO-C) was identified, which has a crystalline, apolar s

66 The influence of the different PCO types and the IOL/PC distance on the total-pulse ene

67 concentration of atmospheric carbon dioxide (PCO(2)) are mostly unknown.

68 concentration of atmospheric carbon dioxide (PCO(2)) near the Triassic-Jurassic boundary.

69 oride are sufficiently suppressed for direct PCO(2) measurements in freshwater samples at pH 8.

70 resembling human polycystic ovarian disease (PCO) and a decrease in the ovarian primordial follicle p

71 We interpret each PCO(2) increase as a direct response to magmatic activit

72 understanding of how the IOL design effects PCO has also advanced.

73 s, after reductive elimination of the entire PCO group, the unprecedented [L2 Ge-GeL2 ] complex 3 in

74 In this study, we estimate PCO(2) from stable isotopic values of pedogenic carbonat

75 at rest and during exercise in 19 eucapnic (PCO(2) 40 +/- 3 mm Hg), and 13 hypercapnic (PCO(2) 52 +/

76 highest energy was required for the fibrosis PCO type, followed by mixed, pearl and late-postoperativ

77 documentation was performed and analyzed for PCO using Evaluation of Posterior Capsule Opacification

78 f IOL was the most important risk factor for PCO in this study, whereas intrinsic proliferative capac

79 ract patients, to determine risk factors for PCO and to investigate possible association with growth

80 re rotated to give a total of 120 images for PCO assessment.

81 The model for PCO in vitro consisted of an IOL placed on a membrane co

82 minum garnet posterior capsulotomy rates for PCO were similar in the PEX group when compared with con

83 ey structural elements that are required for PCO activity and provide a platform for engineering crop

84 g novel potential therapeutic strategies for PCO, our findings extend the so-called TGFbeta paradox,

85 oherence tomography (OCT) as a technique for PCO analysis.

86 e potential to become an additional tool for PCO characterization.

87 n patients who did not receive treatment for PCO (median 75 years, p = 0.022).

88 Data on treatment/no treatment for PCO was obtained from 270 patients with a median follow-

89 ation is expected to overestimate functional PCO severity.

90 lysis software was used to objectively grade PCO density from standardized, high-resolution retroillu

91 ickly reduce her FET(CO(2)) to 4.2%, but her PCO(2) did not change after administration of acetazolam

92 intact ventilatory response to exercise; her PCO(2) was high at the start of exercise and increased s

93 High PCO did not change pHi at PO2 of 120-135 Torr, showing t

94 (PCO(2) 40 +/- 3 mm Hg), and 13 hypercapnic (PCO(2) 52 +/- 10 mm Hg) patients with severe COPD.

95 (PO(2)=10-15 Torr) increased and hypocapnia (PCO(2)=7-9 Torr) decreased the cytoplasmic calcium [Ca(2

96 No significant change in PCO was observed between 3 and 5 years within the capsul

97 The systematic decreases in PCO(2) after each magmatic episode probably reflect cons

98 ed a statistically significant difference in PCO and neodymium:yttrium-aluminum-garnet capsulotomy ra

99 The increase in PCO up to 3 years was significant.

100 There was a significant increase in PCO up to 3 years.

101 As occurs in PCO, lens cells in this model proliferated, migrated acr

102 A rise in PCO(2) activates the carotid bodies and exerts additiona

103 arp posterior optic edge plays a key role in PCO development.

104 Stabilization in PCO was observed between 3 and 5 years with no differenc

105 outcomes measures in GAS cohorts, including PCOs, complications, and functional outcomes.

106 d the posterior lens capsule seem to inhibit PCO to a greater degree.

107 by hydrolysis of the phosphaethynolate ion (PCO(-) ).

108 red at 130-136 days gestation failed to keep PCO(2) below 100 mm Hg by 2 hours.

109 Li-PCO and Li-CCO values were lower than simultaneously obt

110 Li-PCO gives a measurement that agrees well with Li-CCO.

111 Li-PCO provides accurate measurements of CO without the ris

112 6-11.52 L/min (mean, 5.22 L/min; n = 31); Li-PCO, 1.63-9.99 L/min (mean, 5.22 L/min; n = 31), and TDC

113 ood linear correlation between Li-CCO and Li-PCO (R2 =.845).

114 Serial measurements of Li-CCO and Li-PCO were made during hemodynamically stable conditions.

115 The mean difference for Li-CCO-Li-PCO was smaller if the peripheral injection site was pro

116 The mean difference for Li-CCO-Li-PCO was very small and insignificant (p =.97), and the l

117 enous administration of lithium chloride (Li-PCO) with Li-CCO.

118 imultaneously obtained TDCO measurements (Li-PCO-TDCO, -0.538 +/- 0.95 L/min, p =.003; Li-CCO-TDCO, -

119 Accuracy of Li-PCO is probably improved if a proximal arm vein is used.

120 There were 93 Li-CCOs, 93 Li-PCOs, and 216 TDCOs recorded.

121 R indicates that logMAR is unaffected by low PCO severity.

122 s) indicates that log(s) is sensitive to low PCO severity, whereas the curvilinear relation between P

123 c Vivinex XY1 IOL showed significantly lower PCO rates and lower YAG rates compared to the AcrySof SN

124 d the hyperemic response to elevated luminal PCO(2) in the duodenum of anesthetized rats luminally ex

125 vides a therapeutic target to further manage PCO development and will yield best results when used in

126 In group A, the mean PCO score was significantly lower in the SE-PMMA IOL eye

127 In group B, the mean PCO score was statistically lower in the SE-PMMA IOL eye

128 etalloproteinases (MMPs) in TGFbeta-mediated PCO formation.

129 l endothelial cells (BCECs) affects membrane PCO(2).

130 rent arteriolar dilator response to 1 microM PCO-400 (a benzopyran K(ATP) agonist) was also accentuat

131 Predominantly mild PCO occurred in one-third of eyes after phacoemulsificat

132 ia: institution of CPB, antegrade myocardial PCO perfusion without recirculation (500 mL of 50 mumol/

133 The mean objective PCO score of the Vivinex XY1 IOLs was 0.9 +/- 0.8 compar

134 The objective PCO score (mean +/- standard deviation) was 3.0 +/- 2.0

135 function after permanent coronary occlusion (PCO) and the potential involvement of the protective pro

136 thoracotomy and treatment in the absence of PCO.

137 educe observer bias and increase accuracy of PCO grading.

138 The amount of PCO (score: 0-10) was assessed subjectively at the slit

139 IOL) designs that have reduced the amount of PCO following surgery have been made.

140 Thus the application of PCO pretreatment as a protective strategy in the setting

141 Associations of PCO with surgeon groups and different types of implanted

142 referral, especially in less severe cases of PCO.

143 The following is an ex vivo comparison of PCO between the Clareon vs. the AcrySof IOL in human cap

144 r histopathological differences in degree of PCO between the TGF-beta2- and FCS/PBS-treated groups at

145 has the potential to suppress development of PCO and provide potential therapeutic benefit to catarac

146 good candidates for blocking development of PCO.

147 Comparisons of the EAs of PCO(*) and PCS(*) with the previously measured EA values

148 cond study determined whether the effects of PCO pretreatment could be translated to an in vivo model

149 nder the IOL and preventing the formation of PCO after cataract surgery.

150 e has been found in the ex vivo formation of PCO between the two IOLs.

151 d by TGF-beta2 and SPARC in the formation of PCO.

152 of the ECM-cell interaction in formation of PCO.

153 ctron density from phosphorus in the HOMO of PCO(-) to sulfur in the HOMO of PCS(-).

154 rongly believe that the overall incidence of PCO and hence the incidence of Nd:YAG laser posterior ca

155 There was a low incidence of PCO in eyes with total anterior capsule cover over the I

156 Three-year cumulative incidence of PCO was 38.5% (95% confidence interval [CI] 36.1%-40.9%)

157 The three-year cumulative incidence of PCO was 5.2% and the cumulative 5-year incidence was 11.

158 Cumulative incidence of PCO was estimated using Kaplan-Meier methods.

159 Additionally, we evaluate the influence of PCO types and the distance between the intraocular lens

160 Rational manipulation of PCO activity could regulate ERF-VII levels and improve f

161 to study mechanisms involved in the onset of PCO.

162 ctrochemically pumping oxygen into or out of PCO films, leading to measurable film volume changes due

163 tial therapeutic target in the prevention of PCO.

164 s a therapeutic target for the prevention of PCO.

165 Progression of PCO involved early activation of SFKs.

166 of UDVA and BDVA as well as similar rates of PCO after cataract surgery.

167 elastics were utilized ex vivo, and rates of PCO formation were analyzed.

168 Recalibration of PCO was performed every 8 hrs.

169 ular lens (IOL) were associated with risk of PCO, with hydrophilic 1-piece IOLs conferring a higher r

170 ovides a novel strategy for the treatment of PCO and potentially other fibrotic disorders.

171 em developed proved to classify six types of PCO.

172 t of TGF-beta2 or anti-TGF-beta2 antibody on PCO was found in rodents at the dose and timing administ

173 ion of the effects of SPARC and TGF-beta2 on PCO in vitro.

174 red the role of growth factor restriction on PCO using human lens cell and tissue culture models.

175 x (ECM) in posterior capsular opacification (PCO) in vitro.

176 Posterior capsular opacification (PCO) is caused by the proliferation, migration, and epit

177 ibition on posterior capsular opacification (PCO) with the use of a pig eye capsular bag model.

178 lopment of posterior capsular opacification (PCO).

179 aracts and posterior capsular opacification (PCO).

180 agement of posterior capsular opacification (PCO).

181 (ACO), and posterior capsular opacification (PCO).

182 mon AE was posterior capsular opacification (PCO; 748 eyes, incidence 4.0%).

183 Posterior capsule opacification (PCO) after cataract surgery is influenced by intraocular

184 e long-term posterior capsule opacification (PCO) and neodymium-doped yttrium aluminium garnet (Nd:YA

185 Posterior capsule opacification (PCO) arises because of a persistent growth of lens epith

186 OL) design, posterior capsule opacification (PCO) arising from lens cell growth remains a major probl

187 ns disorder posterior capsule opacification (PCO) develops in millions of patients following cataract

188 QUA II]) of posterior capsule opacification (PCO) in high-resolution digital retroillumination images

189 Posterior capsule opacification (PCO) is a complication of cataract surgery resulting fro

190 Posterior capsule opacification (PCO) is the most common complication following primary c

191 Posterior capsule opacification (PCO) is the most common post-operative complication asso

192 lication of posterior capsule opacification (PCO) or secondary cataract.

193 ncidence of posterior capsule opacification (PCO) requiring Nd:YAG laser capsulotomy in a representat

194 symptomatic posterior capsule opacification (PCO) underwent Nd:YAG laser capsulotomy.

195 ulotomy for posterior capsule opacification (PCO), and visual acuity (VA) in eyes with and without ps

196 e, known as posterior capsule opacification (PCO), following cataract surgery.

197 ributing to posterior capsule opacification (PCO).

198 nt model of posterior capsule opacification (PCO).

199 re model of posterior capsule opacification (PCO).

200 surgery is posterior capsule opacification (PCO; secondary cataract).

201 cidence of posterior capsule opacification, (PCO, secondary cataract) and hence the need for Nd:YAG l

202 nical Oncology Provisional Clinical Opinion (PCO) offers timely clinical direction after publication

203 ncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membersh

204 ncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membersh

205 An ASCO provisional clinical opinion (PCO) offers timely clinical direction to ASCO's membersh

206 ncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to the ASCO member

207 ncology (ASCO) provisional clinical opinion (PCO) on the integration of palliative care into standard

208 ncology (ASCO) provisional clinical opinion (PCO), offers timely clinical direction to ASCO's oncolog

209 Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publi

210 NOTE: ASCO's provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidenc

211 ASCO's provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidenc

212 ASCO's provisional clinical opinions (PCOs) reflect expert consensus based on clinical evidenc

213 ive survival were used to define the optimal PCO(2) range.

214 in outcomes for patients within this optimal PCO(2) range for nonintubated patients after adjusting f

215 ion to the evidence reviewed in the original PCO, 11 systematic reviews with meta-analyses, two retro

216 The PLANT CYSTEINE OXIDASEs (PCOs) have been identified as catalysts of this oxidatio

217 n of oxygen-sensing plant cysteine oxidases (PCOs).

218 cyanide insensitive palmitoyl CoA oxidation (PCO) and caused activation of nuclear factor kappa beta

219 52 patients and nine normal subjects for pH, PCO(2), and concentrations of plasma electrolytes and pr

220 t the sensor is equally useful for gas-phase PCO(2) measurements.

221 the synthetically valuable phosphaketenide (PCO(-)) ligand and a phosphinidene germylene complex, re

222 the routine environmental and physiological PCO(2) levels.

223 The RE-PMMA PCO rate did not plateau and continued to increase throu

224 del coupled to a carbon-cycle model predicts PCO(2) increases of less than 400 ppm from magmatic vola

225 d whether the inhibition of SFKs can prevent PCO.

226 ibition as a therapeutic strategy to prevent PCO.

227 Therefore, exposure to PP1 prevented PCO.

228 the initial phospholane, reaction products (PCO/POC-isomers), and an intermediate P(V)-oxaphosphiran

229 e first time not only objectively quantifies PCO, but also qualitatively assesses PCO in an automated

230 le and posterior capsules and further reduce PCO incidence.

231 on in hypoxia presumably arises from reduced PCO activity.

232 hom information could be retrieved regarding PCO treatment, in vitro cell culture could be establishe

233 potential therapeutic approach to resolving PCO.

234 he linear relation between retroillumination PCO severity and log(s) indicates that log(s) is sensiti

235 ising out of or related to any use of ASCO's PCOs, or for any errors or omissions.

236 Severe PCO was defined if the view of the optic disc was obscur

237 A data set of 100 eyes with no to severe PCO was analysed.

238 ncluding 4.7% (95% CI 3.5%-5.8%) with severe PCO.

239 f IOL (p = 0.005, 15.7 days) showed a slower PCO development in comparison to the control (8.6 days).

240 ls seems to be less important for subsequent PCO development.

241 5' akin to the analogous phosphorus system, [PCO](-) .

242 Other than PCO, postoperative macular issues were the most common c

243 tion was related to PCO severity rather than PCO morphology.

244 We directly demonstrate that PCO dioxygenase activity produces Cys-sulfinic acid at t

245 Thermogravimetric analysis showed that PCO-C had high thermal stability and high UV absorption

246 The PCO controls received water.

247 The PCO plus (-)-epicatechin group values were comparable wi

248 The PCO scores and Nd:YAG capsulotomy rate.

249 The PCO severity (EPCO score) assessed with retroilluminatio

250 The PCO severity was assessed with retroillumination using e

251 tend to cause overestimation of LiCO by the PCO.

252 terised, including a compound containing the PCO(-) anion in an unprecedented mu(2) :eta(2) ,eta(2) -

253 ly the topics specifically identified in the PCO and are not applicable to interventions, diseases or

254 Progression of proliferation and EMT in the PCO cultures was determined by Western blot analysis and

255 lution in dichloromethane for one month, the PCO-isomer rearranges into the thermodynamically more st

256 is an oxygen (O(2) )-regulated target of the PCO branch of the PRT6 N-degron pathway of ubiquitin-med

257 Mild hydrolysis of the PCO/POC-isomers proceeds with a high chemoselectivity an

258 ed hypercapnia, PET(CO(2)) overestimates the PCO(2) at the central chemoreceptors.

259 Our study indicates that the PCO types and the IOL/PC distance influence the total-pu

260 nex XY1 IOLs was 0.9 +/- 0.8 compared to the PCO score of 1.4 +/- 1.1 for the AcrySof SN60WF IOLs (P

261 haheteroallenes (NHP)-O-P=C=NHC in which the PCO unit has been isomerized to OPC.

262 acetylenes and nitriles as well as with the PCO(-) anion.

263 The PCOs and ATE1 may be viable intervention targets to stab

264 The PCOs are therefore a vital component of the plant oxygen

265 The PCOs catalyze the reaction of oxygen with the conserved

266 The structures reveal that the PCOs comprise a cupin-like scaffold, which supports a ce

267 tures are not conserved, suggesting that the PCOs may use divergent mechanisms to oxidize their subst

268 This PCO addresses identification and management of patients

269 This PCO addresses recommendations for chronic hepatitis B vi

270 This PCO addresses second-line hormonal therapy for chemother

271 This PCO addresses the clinical utility of using epidermal gr

272 This PCO addresses the integration of palliative care service

273 This PCO addresses the role of prostate-specific antigen (PSA

274 This PCO addresses the utility of KRAS gene mutation testing

275 This PCO update addresses the utility of extended RAS gene mu

276 als and expert consensus opinion inform this PCO.

277 ity systematic review primarily informs this PCO on the benefits and harms of PSA-based screening.

278 Seven published RCTs form the basis of this PCO.

279 hemotherapy doublets, form the basis of this PCO.

280 g growth factor beta (TGFbeta) is central to PCO development.

281 AQP1 does not contribute to PCO(2) in corneal endothelial cells.

282 uding eyes where the loss of CDVA was due to PCO; the majority of these were due to macular causes.

283 The duodenal mucosa is exposed to PCO(2) >200 mm Hg due to the luminal mixture of gastric

284 epithelial mesenchymal transition linked to PCO.

285 Visual function deterioration was related to PCO severity rather than PCO morphology.

286 of the contribution of calcium-signaling to PCO.

287 90 nM (n=6) at normoxia (PO(2)=125-130 Torr, PCO(2)=25-30 Torr, pH 7.30-7.35).

288 work and effort while independently varying PCO(2) or the level of targeted voluntary breathing.

289 ed HA resulted in increased rates of ex vivo PCO suggesting that judicious selection and use of visco

290 ions of HA led to increased rates of ex vivo PCO.

291 The main outcome measure was PCO score (scale, 0 to 10) assessed subjectively at the

292 At 3 weeks, PCO control animals demonstrated significant increases i

293 air hunger ratings changed more steeply when PCO(2) was altered and ventilation was constant; work or

294 of the present study was to examine whether PCO pretreatment would provide protective effects on lef

295 ossible predisposing factors associated with PCO development include surgery performed by ophthalmolo

296 study population, 240 pseudophakic eyes with PCO and a capsulotomy indication were selected.

297 d width of the ACA in pseudophakic eyes with PCO increased significantly after Nd:YAG laser capsuloto

298 47 eyes with PCO scheduled for the Nd:YAG procedure were examined and

299 improvement in contractile performance with PCO pretreatment was confounded by refractory arrhythmog

300 nce population, 99 pseudophakic eyes without PCO were selected.

301 those of a control group of 15 eyes without PCO.